Saeed Rafii

2.1k total citations · 1 hit paper
34 papers, 1.5k citations indexed

About

Saeed Rafii is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Saeed Rafii has authored 34 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 14 papers in Molecular Biology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Saeed Rafii's work include PARP inhibition in cancer therapy (7 papers), BRCA gene mutations in cancer (5 papers) and HER2/EGFR in Cancer Research (5 papers). Saeed Rafii is often cited by papers focused on PARP inhibition in cancer therapy (7 papers), BRCA gene mutations in cancer (5 papers) and HER2/EGFR in Cancer Research (5 papers). Saeed Rafii collaborates with scholars based in United Kingdom, United States and France. Saeed Rafii's co-authors include Zev A. Wainberg, John A. Blake-Haskins, Winston Tan, Peter H. O’Donnell, Marlon C. Rebelatto, Xiaoping Jin, Jason J. Luke, Tyler J. Curiel, John F. Kurland and Christophe Massard and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Saeed Rafii

34 papers receiving 1.5k citations

Hit Papers

Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Pro... 2016 2026 2019 2022 2016 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
    2016 661 citations Christophe Massard, Michael S. Gordon et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Saeed Rafii United Kingdom 13 1.0k 516 395 242 231 34 1.5k
Alexander C. Klimowicz Canada 23 653 0.6× 821 1.6× 182 0.5× 121 0.5× 188 0.8× 56 1.5k
B Iacopetta Australia 24 1.2k 1.2× 741 1.4× 328 0.8× 110 0.5× 304 1.3× 46 2.0k
Johanne I. Weberpals Canada 20 619 0.6× 687 1.3× 176 0.4× 101 0.4× 133 0.6× 56 1.3k
Paul J. van Diest Netherlands 22 549 0.5× 833 1.6× 158 0.4× 90 0.4× 184 0.8× 40 1.6k
Sanjeeve Balasubramaniam United States 17 454 0.4× 280 0.5× 172 0.4× 177 0.7× 149 0.6× 33 920
Hongyong He China 22 784 0.8× 546 1.1× 255 0.6× 685 2.8× 490 2.1× 63 1.7k
Hong Zheng China 13 569 0.6× 632 1.2× 104 0.3× 505 2.1× 118 0.5× 67 1.4k
Matin Sheriff United Kingdom 16 551 0.5× 364 0.7× 168 0.4× 117 0.5× 193 0.8× 33 1.0k
Maja J.A. de Jonge Netherlands 19 848 0.8× 865 1.7× 125 0.3× 121 0.5× 420 1.8× 40 1.6k
Jonathan C. Dudley United States 15 937 0.9× 380 0.7× 475 1.2× 129 0.5× 495 2.1× 24 1.5k

Countries citing papers authored by Saeed Rafii

Since Specialization
Citations

This map shows the geographic impact of Saeed Rafii's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Saeed Rafii with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Saeed Rafii more than expected).

Fields of papers citing papers by Saeed Rafii

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Saeed Rafii. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Saeed Rafii. The network helps show where Saeed Rafii may publish in the future.

Co-authorship network of co-authors of Saeed Rafii

This figure shows the co-authorship network connecting the top 25 collaborators of Saeed Rafii. A scholar is included among the top collaborators of Saeed Rafii based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Saeed Rafii. Saeed Rafii is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rafii, Saeed, et al.. (2025). Advancing CAR T-Cell Therapy in Solid Tumors: Current Landscape and Future Directions. Cancers. 17(17). 2898–2898. 3 indexed citations
2.
Fadhil, Ibtihal, et al.. (2025). Cancer control in the United Arab Emirates. The Lancet Oncology. 26(7). e381–e389. 3 indexed citations
3.
Macpherson, Iain R., Pavlina Spiliopoulou, Saeed Rafii, et al.. (2019). A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. Breast Cancer Research. 22(1). 1–1. 48 indexed citations
4.
Lindeman, Geoffrey J., Aditya Bardia, Rebecca Bowen, et al.. (2019). Randomized phase II trial of venetoclax + fulvestrant versus fulvestrant in estrogen receptor+, HER2– locally advanced or metastatic breast cancer following recurrence or progression during or after a CDK4/6 inhibitor: VERONICA.. Journal of Clinical Oncology. 37(15_suppl). TPS1108–TPS1108. 2 indexed citations
5.
Bono, Johann S. de, Ramesh K. Ramanathan, Lida A. Mina, et al.. (2017). Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. Cancer Discovery. 7(6). 620–629. 314 indexed citations
6.
Sundar, Sudha, Janos Balega, Emma J. Crosbie, et al.. (2017). BGCS uterine cancer guidelines: Recommendations for practice. European Journal of Obstetrics & Gynecology and Reproductive Biology. 213. 71–97. 108 indexed citations
7.
8.
Moschetta, Michele, Benjamin Kasenda, Gabriel Mak, et al.. (2016). Dynamics of neutrophil to lymphocyte ratio (NLR) predict effectiveness of PD1/PDL1 inhibition. Annals of Oncology. 27. vi24–vi24. 2 indexed citations
9.
Dean, Emma, Nicola Steele, Hendrik‐Tobias Arkenau, et al.. (2016). SELECT-3: A phase I study of selumetinib in combination with platinum doublet chemotherapy for advanced NSCLC in the first-line setting. Annals of Oncology. 27. vi439–vi439. 2 indexed citations
10.
Massard, Christophe, Michael S. Gordon, Sunil Sharma, et al.. (2016). Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. Journal of Clinical Oncology. 34(26). 3119–3125. 661 indexed citations breakdown →
11.
Harvey, R. Donald, Nicolás Isambert, Saeed Rafii, et al.. (2016). Effect of multiple-dose osimertinib (AZD9291) on the pharmacokinetics (PK) of simvastatin and rosuvastatin.. Journal of Clinical Oncology. 34(15_suppl). e14098–e14098. 5 indexed citations
12.
Rafii, Saeed, Desamparados Roda, Elena Geuna, et al.. (2015). Higher Risk of Infections with PI3K–AKT–mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials. Clinical Cancer Research. 21(8). 1869–1876. 28 indexed citations
13.
Geuna, Elena, Desamparados Roda, Saeed Rafii, et al.. (2015). Complications of hyperglycaemia with PI3K–AKT–mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials. British Journal of Cancer. 113(11). 1541–1547. 27 indexed citations
14.
Rafii, Saeed, et al.. (2013). Is uterine serous carcinoma a part of hereditary breast cancer syndrome?. Journal of Clinical Oncology. 31(15_suppl). 5587–5587. 1 indexed citations
15.
Vatankhah, Soudabeh, et al.. (2012). Driving to contract management in health care institutes of developing countries.. PubMed. 14(4). 235–9. 1 indexed citations
16.
Rafii, Saeed. (2010). The role of maintenance pemetrexed in the treatment of non-small-cell lung cancer. PubMed. 1. 101–101. 1 indexed citations
17.
Rafii, Saeed, et al.. (2006). Mitotic defects in XRCC3 variants T241M and D213N and their relation to cancer susceptibility. Human Molecular Genetics. 15(7). 1217–1224. 33 indexed citations
18.
19.
Rafii, Saeed. (2002). A potential role for the XRCC2 R188H polymorphic site in DNA-damage repair and breast cancer. Human Molecular Genetics. 11(12). 1433–1438. 96 indexed citations
20.
Young, Lucy H., C C Liu, Sanjay V. Joag, Saeed Rafii, & John Ding‐E Young. (1990). How Lymphocytes Kill. Annual Review of Medicine. 41(1). 45–54. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alexander C. Klimowicz Breakdown of academic impact, for papers by B Iacopetta Breakdown of academic impact, for papers by Johanne I. Weberpals Breakdown of academic impact, for papers by Paul J. van Diest Breakdown of academic impact, for papers by Sanjeeve Balasubramaniam Breakdown of academic impact, for papers by Hongyong He Breakdown of academic impact, for papers by Hong Zheng Breakdown of academic impact, for papers by Matin Sheriff Breakdown of academic impact, for papers by Maja J.A. de Jonge Breakdown of academic impact, for papers by Jonathan C. Dudley
Rankless by CCL
2026